Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lipocine (LPCN) Other Accumulated Expenses (2017 - 2022)

Lipocine (LPCN) has disclosed Other Accumulated Expenses for 4 consecutive years, with $1.0 million as the latest value for Q1 2022.

  • For the quarter ending Q1 2022, Other Accumulated Expenses changed N/A year-over-year to $1.0 million, compared with a TTM value of $1.0 million through Mar 2022, changed N/A, and an annual FY2021 reading of $1.0 million, changed N/A over the prior year.
  • Other Accumulated Expenses was $1.0 million for Q1 2022 at Lipocine, roughly flat from $1.0 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $4.2 million in Q1 2018 and bottomed at $1.0 million in Q3 2021.
  • Average Other Accumulated Expenses over 3 years is $2.0 million, with a median of $1.0 million recorded in 2021.